Want to see AZR full AI Analyst Report?
Azora Therapeutics (AZR) Ratios
Azora Therapeutics Ratios
AZR's free cash flow for Q2 2026 was $-6.36M. For the 2026 fiscal year, AZR's free cash flow was increased by $0.00 and operating cash flow was $-6.36M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.42 | 4.16 | 4.90 | 2.67 | 2.37 |
| Quick Ratio | 4.42 | 4.16 | 4.90 | 2.67 | 2.37 |
| Cash Ratio | 4.21 | 3.84 | 4.33 | 2.23 | 2.23 |
| Solvency Ratio | -5.24 | -13.52 | -10.71 | -5.18 | -4.69 |
| Operating Cash Flow Ratio | -4.65 | -7.09 | -10.42 | -6.25 | -4.39 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -240.99 |
| Net Current Asset Value | $ 4.66M | $ 3.08M | $ 2.55M | $ 2.32M | $ 2.34M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.06 | 0.07 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.06 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.29 | 1.24 | 1.16 | 1.75 | 2.18 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -354.77 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.20 | 0.35 |
| Net Debt to EBITDA | 0.74 | 0.28 | 0.40 | 0.35 | 0.33 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 117.93% | 99.52% |
| EBT Per EBIT | 102.28% | 159.30% | 101.65% | 99.42% | 101.19% |
| Return on Assets (ROA) | -117.34% | -261.65% | -147.81% | -222.08% | -254.44% |
| Return on Equity (ROE) | -151.18% | -324.41% | -171.47% | -388.57% | -553.72% |
| Return on Capital Employed (ROCE) | -144.40% | -203.65% | -168.66% | -275.49% | -392.73% |
| Return on Invested Capital (ROIC) | -144.40% | -203.65% | -168.66% | -271.57% | -386.93% |
| Return on Tangible Assets | -117.39% | -261.82% | -147.93% | -222.25% | -263.19% |
| Earnings Yield | -216.92% | -70.29% | -264.24% | -217.76% | -38.70% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -82440.17 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 82440.17 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -9.71 | -9.31 | -4.78 | -10.52 | -16.07 |
| Free Cash Flow Per Share | -9.71 | -9.31 | 0.00 | -10.52 | -16.16 |
| Dividend Paid and CapEx Coverage Ratio | -2164201.00 | 0.00 | -1.00 | 0.00 | -184.96 |
| Capital Expenditure Coverage Ratio | -2164201.00 | 0.00 | -1.00 | 0.00 | -184.96 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -53.94 | -46.50 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -176.55% | -36.87% | 0.00% | -191.32% | -23.94% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.46 | -1.42 | -0.38 | -0.46 | -2.58 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.70 | 4.62 | 0.65 | 1.78 | 14.31 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.57 | -2.71 | 0.00 | -0.52 | -4.18 |
| Price-to-Operating Cash Flow Ratio | -0.57 | -2.71 | -0.39 | -0.52 | -4.20 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.02 | 0.01 | 0.01 | -0.13 |
| Enterprise Value Multiple | 0.28 | -1.14 | 0.03 | -0.19 | -2.51 |
| Enterprise Value | -2.20M | 15.02M | -177.21K | 2.05M | 44.38M |
| EV to EBITDA | 0.28 | -1.14 | 0.03 | -0.19 | -2.51 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.34 | -2.17 | 0.00 | -0.18 | -3.69 |
| EV to Operating Cash Flow | 0.34 | -2.17 | 0.03 | -0.18 | -3.71 |
| Tangible Book Value Per Share | 7.89 | 5.47 | 2.86 | 3.08 | 4.38 |
| Shareholders’ Equity Per Share | 7.89 | 5.47 | 2.87 | 3.08 | 4.72 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -11.93 | -17.75 | -4.91 | -11.98 | -26.12 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.18 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 0.99 | 1.10 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.81 | 0.52 | 0.97 | 0.88 | 0.62 |
Currency in USD
